Imeglimin

• CAT Number: I004855
• CAS Number: 775351-65-0
• Molecular Formula: C6H13N5
• Molecular Weight: 155.2
• Purity: ≥95%
• Target: AMPK
• Solubility: 10 mM in DMSO
• Storage: Store at -20C
• InChI: InChI=1S/C6H13N5/c1-4-8-5(7)10-6(9-4)11(2)3/h4H,1-3H3,(H3,7,8,9,10)/t4-/m0/s1
• InChIKey: GFICWFZTBXUVIG-BYPYZUCNSA-N
• SMILES: NC1=N[C@H](C)NC(N(C)C)=N1

Imeglimin (Cat No.:I004855) is the first of a new class of oral antidiabetic drugs containing tetrahydrotriazine – gliadin; it has been shown to act on liver, muscle and pancreatic beta cells, uniquely targeting the key defect in type 2 diabetes.

Reference

1:Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration. Detaille D, Vial G, Borel AL, Cottet-Rouselle C, Hallakou-Bozec S, Bolze S, Fouqueray P, Fontaine E.Cell Death Discov. 2016 Jan 18;2:15072. doi: 10.1038/cddiscovery.2015.72. eCollection 2016. PMID: 27551496 Free PMC Article2:Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents. Perry RJ, Cardone RL, Petersen MC, Zhang D, Fouqueray P, Hallakou-Bozec S, Bolze S, Shulman GI, Petersen KF, Kibbey RG.Am J Physiol Endocrinol Metab. 2016 Aug 1;311(2):E461-70. doi: 10.1152/ajpendo.00009.2016. Epub 2016 Jul 12. PMID: 27406738 3:Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes. Vuylsteke V, Chastain LM, Maggu GA, Brown C.Drugs R D. 2015 Sep;15(3):227-32. doi: 10.1007/s40268-015-0099-3. Review. PMID: 26254210 Free PMC Article4:Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes. Pacini G, Mari A, Fouqueray P, Bolze S, Roden M.Diabetes Obes Metab. 2015 Jun;17(6):541-5. doi: 10.1111/dom.12452. Epub 2015 Mar 25. PMID: 25694060 5:Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model. Vial G, Chauvin MA, Bendridi N, Durand A, Meugnier E, Madec AM, Bernoud-Hubac N, Pais de Barros JP, Fontaine É, Acquaviva C, Hallakou-Bozec S, Bolze S, Vidal H, Rieusset J.Diabetes. 2015 Jun;64(6):2254-64. doi: 10.2337/db14-1220. Epub 2014 Dec 31. PMID: 25552598 Free Article6:The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy. Fouqueray P, Pirags V, Diamant M, Schernthaner G, Lebovitz HE, Inzucchi SE, Bailey CJ.Diabetes Care. 2014 Jul;37(7):1924-30. doi: 10.2337/dc13-2349. Epub 2014 Apr 10. PMID: 24722500 7:The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Fouqueray P, Pirags V, Inzucchi SE, Bailey CJ, Schernthaner G, Diamant M, Lebovitz HE.Diabetes Care. 2013 Mar;36(3):565-8. doi: 10.2337/dc12-0453. Epub 2012 Nov 16. PMID: 23160726 Free PMC Article8:Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. Pirags V, Lebovitz H, Fouqueray P.Diabetes Obes Metab. 2012 Sep;14(9):852-8. doi: 10.1111/j.1463-1326.2012.01611.x. Epub 2012 May 16. PMID: 22519919